U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H11Cl2O4.Na
Molecular Weight 325.12
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETHACRYNATE SODIUM

SMILES

[Na+].CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC([O-])=O)C=C1

InChI

InChIKey=CWCSCNSKBSCYCS-UHFFFAOYSA-M
InChI=1S/C13H12Cl2O4.Na/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17;/h4-5H,2-3,6H2,1H3,(H,16,17);/q;+1/p-1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/16092s042,16093s044lbl.pdf

Ethacrynic acid is a monosulfonamyl loop or high ceiling diuretic. Ethacrynic acid acts on the ascending limb of the loop of Henle and on the proximal and distal tubules. Urinary output is usually dose dependent and related to the magnitude of fluid accumulation. Water and electrolyte excretion may be increased several times over that observed with thiazide diuretics, since ethacrynic acid inhibits reabsorption of a much greater proportion of filtered sodium than most other diuretic agents. Therefore, ethacrynic acid is effective in many patients who have significant degrees of renal insufficiency. Ethacrynic acid has little or no effect on glomerular filtration or on renal blood flow, except following pronounced reductions in plasma volume when associated with rapid diuresis. Ethacrynic acid inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. Diuretics also lower blood pressure initially by reducing plasma and extracellular fluid volume; cardiac output also decreases, explaining its antihypertensive action. Eventually, cardiac output returns to normal with an accompanying decrease in peripheral resistance. Its mode of action does not involve carbonic anhydrase inhibition. Ethacrynic acid is indicated for the treatment of high blood pressure and edema caused by diseases like congestive heart failure, liver failure, and kidney failure.

CNS Activity

Curator's Comment: Ethacrynic acid does not cross the blood-brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Glutathione transferases, rat liver
Target ID: P05023|||Q9UJ20
Gene ID: 476.0
Gene Symbol: ATP1A1
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
EDECRIN

Approved Use

EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable.

Launch Date

1967
Primary
EDECRIN

Approved Use

EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable.

Launch Date

1967
Doses

Doses

DosePopulationAdverse events​
50 mg 2 times / day multiple, oral
Dose: 50 mg, 2 times / day
Route: oral
Route: multiple
Dose: 50 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: edema
Sex: unknown
Sources:
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (severe)
Sources:
AEs

AEs

AESignificanceDosePopulation
Diarrhea severe
Disc. AE
50 mg 2 times / day multiple, oral
Dose: 50 mg, 2 times / day
Route: oral
Route: multiple
Dose: 50 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: edema
Sex: unknown
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 0.58 uM]
yes [IC50 121 uM]
yes [IC50 29.6 uM]
yes [IC50 8.76 uM]
Drug as victim

Drug as victim

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Ethacrynic acid-induced convulsions and brain neurotransmitters in mice.
1992 Oct 6
The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance.
2000 Aug
Rat liver microsomal lipid peroxidation produced during the oxidative metabolism of ethacrynic acid.
2001 Apr
Quantitative imaging of glutathione in hippocampal neurons and glia in culture using monochlorobimane.
2001 Dec 1
Glutathione transferase activities in renal carcinomas and adjacent normal renal tissues: factors influencing renal carcinogenesis induced by xenobiotics.
2001 Jan
Induction of glutathione S-transferase activity and protein expression in brown bullhead (Ameiurus nebulosus) liver by ethoxyquin.
2001 Jul
Chloride channel antagonists perturb growth and morphology of Neurospora crassa.
2001 Jul 24
Differential induction of glutathione S-transferases in the clam Ruditapes decussatus exposed to organic compounds.
2001 Mar
Determination and multivariate statistical analysis of biochemical responses to environmental contaminants in feral freshwater fish Leuciscus cephalus, L.
2001 May
Ethacrynic acid inhibits pancreatic exocrine secretion.
2001 Nov
Decreased glutathione S-transferase expression and activity and altered sex steroids in Lake Apopka brown bullheads (Ameiurus nebulosus).
2001 Nov 12
Sensitization to the cytotoxicity of melphalan by ethacrynic acid and hyperthermia in drug-sensitive and multidrug-resistant Chinese hamster ovary cells.
2001 Sep
Purification and characterization of a glutathione S-transferase from the fungus Cunninghamella elegans.
2001 Sep 25
A putative role for S-nitrosoglutathione as the source of nitric oxide in photorelaxation of the mouse gastric fundus.
2002 Aug 30
Glutathione might exert an important function in caerulein-stimulated amylase release in isolated rat pancreatic acini.
2002 Jan
Peptidomimetic glutathione analogues as novel gammaGT stable GST inhibitors.
2002 Jan
Differential effects of garlic oil and its three major organosulfur components on the hepatic detoxification system in rats.
2002 Jan 16
The organochlorine pesticide residues and antioxidant enzyme activities in human breast tumors: is there any association?
2002 Mar
Glutathione S-transferase of the malarial parasite Plasmodium falciparum: characterization of a potential drug target.
2002 May
Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs.
2002 Nov
Interaction between metamizol and tramadol in a model of acute visceral pain in rats.
2003
Substrate specificity of mouse aldo-keto reductase AKR7A5.
2003 Feb 1
Engineering a new C-terminal tail in the H-site of human glutathione transferase P1-1: structural and functional consequences.
2003 Jan 3
Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine.
2003 Oct
Continuous administration of antisense oligonucleotides to c-fos reduced the development of seizure susceptibility after ethacrynic acid-induced seizure in mice.
2003 Sep 25
Controlled release of ethacrynic acid from poly(lactide-co-glycolide) films for glaucoma treatment.
2004 Aug
Antioxidant gene therapy can protect hearing and hair cells from ototoxicity.
2004 Feb
Effects of pH and the presence of micelles on the resolution of diuretics by reversed-phase liquid chromatography.
2004 Jan 2
Cellular glutathione prevents cytolethality of monomethylarsonic acid.
2004 Mar 1
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Can also be used iv: The usual intravenous dose for the average sized adult is 50 mg, or 0.5 to 1.0 mg per kg of body weight. Usually only one dose has been necessary; occasionally a second dose at a new injection site, to avoid possible thrombophlebitis, may be required. A single intravenous dose not exceeding 100 mg has been used in critical situations
Dosage: To Initiate Diuresis In Adults: The smallest dose required to produce gradual weight loss (about 1 to 2 pounds per day) is recommended. Onset of diuresis usually occurs at 50 to 100 mg for adults. After diuresis has been achieved, the minimally effective dose (usually from 50 to 200 mg daily) may be given on a continuous or intermittent dosage schedule.
Route of Administration: Oral
Ethacrynic acid (10uM) induced both apoptosis and necroptosis in primary CLL cells.
Name Type Language
ETHACRYNATE SODIUM
ORANGE BOOK   USAN   USP   VANDF  
USAN  
Official Name English
Etacrynate sodium [WHO-DD]
Common Name English
ETHACRYNATE SODIUM [USP IMPURITY]
Common Name English
ETACRYNATE SODIUM
WHO-DD  
Common Name English
ETHACRYNIC ACID SODIUM SALT [MI]
Common Name English
SODIUM ETACRYNATE [MART.]
Common Name English
ETHACRYNIC ACID SODIUM SALT
MI  
Common Name English
Sodium [2,3-dichloro-4-(2-methylenebutyryl)phenoxy]acetate
Systematic Name English
ETHACRYNATE SODIUM [USAN]
Common Name English
ACETIC ACID, (2,3-DICHLORO-4-(2-METHYLENE-1-OXOBUTYL)PHENOXY)-, SODIUM SALT
Common Name English
ETHACRYNATE SODIUM [VANDF]
Common Name English
ETHACRYNATE SODIUM [ORANGE BOOK]
Common Name English
SODIUM ETHACRYNATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C49184
Created by admin on Fri Dec 15 15:48:08 GMT 2023 , Edited by admin on Fri Dec 15 15:48:08 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C47993
Created by admin on Fri Dec 15 15:48:08 GMT 2023 , Edited by admin on Fri Dec 15 15:48:08 GMT 2023
PRIMARY
CAS
6500-81-8
Created by admin on Fri Dec 15 15:48:08 GMT 2023 , Edited by admin on Fri Dec 15 15:48:08 GMT 2023
PRIMARY
PUBCHEM
23668825
Created by admin on Fri Dec 15 15:48:08 GMT 2023 , Edited by admin on Fri Dec 15 15:48:08 GMT 2023
PRIMARY
MERCK INDEX
m5042
Created by admin on Fri Dec 15 15:48:08 GMT 2023 , Edited by admin on Fri Dec 15 15:48:08 GMT 2023
PRIMARY Merck Index
FDA UNII
K41MYV7MPM
Created by admin on Fri Dec 15 15:48:08 GMT 2023 , Edited by admin on Fri Dec 15 15:48:08 GMT 2023
PRIMARY
SMS_ID
100000087295
Created by admin on Fri Dec 15 15:48:08 GMT 2023 , Edited by admin on Fri Dec 15 15:48:08 GMT 2023
PRIMARY
EPA CompTox
DTXSID10215320
Created by admin on Fri Dec 15 15:48:08 GMT 2023 , Edited by admin on Fri Dec 15 15:48:08 GMT 2023
PRIMARY
ChEMBL
CHEMBL456
Created by admin on Fri Dec 15 15:48:08 GMT 2023 , Edited by admin on Fri Dec 15 15:48:08 GMT 2023
PRIMARY
EVMPD
SUB01978MIG
Created by admin on Fri Dec 15 15:48:08 GMT 2023 , Edited by admin on Fri Dec 15 15:48:08 GMT 2023
PRIMARY
RXCUI
4108
Created by admin on Fri Dec 15 15:48:08 GMT 2023 , Edited by admin on Fri Dec 15 15:48:08 GMT 2023
PRIMARY RxNorm
DAILYMED
K41MYV7MPM
Created by admin on Fri Dec 15 15:48:08 GMT 2023 , Edited by admin on Fri Dec 15 15:48:08 GMT 2023
PRIMARY
EVMPD
SUB193938
Created by admin on Fri Dec 15 15:48:08 GMT 2023 , Edited by admin on Fri Dec 15 15:48:08 GMT 2023
ALTERNATIVE
DRUG BANK
DBSALT001225
Created by admin on Fri Dec 15 15:48:08 GMT 2023 , Edited by admin on Fri Dec 15 15:48:08 GMT 2023
PRIMARY